Market-leading patient experience data solutions for Lifesciences

We provide the largest archive of online real-world patient experience data worldwide.

Our Solutions

Semalytix has built the single largest archive of patient and physician experience data worldwide. Think of the largest pharmaceutical stakeholder focus group powered by millions of online conversations and analysed by an award-winning AI system.

Observational patient experience research

One observational patient experience report on key research areas: Quality-of-life, experienced symptoms, treatment experiences, and unmet needs is created ten times faster and covers 100-1000 times more patients compared to traditional means.

Validate commercial potential of disease maps / new products

Determine the size and nature of commercial opportunities in new disease areas by measuring unmet needs and quality-of-life burdens in the largest disease-specific focus groups possible.

Improve study design and increase the probability of trial success

Use NLP to create foundational patient understanding for your research, clinical development, and medical teams. Explore new or validate presumed clinical endpoints and risk hedge your study designs against millions of representative real-world patient-experience data points.

Complement Real-World Data strategies

Authorities increasingly demand new and larger-scale sources of real-world data (see Patient-focused drug development guidance). Augment your RWD strategy by tapping into the largest archive of patient experience data worldwide.

Experience-data-driven patient journeys

Add an unprecedented level of authenticity to your patient journeys by listening to a chorus of global patient voices. Learn from thousands of real-world stories of patients, across languages, countries, and time.

Medical text summarisation

Use NLP and generative models to bring together scientific literature, patient data, physician insights, ad-boards, clinical trial documentation, and any other free-form document sources. Experience the power of lletting fact-procted AI summarise millions of documents for you.

Why Semalytix?

Semalytix has a unique blend of experience in natural language processing, machine-learning artificial intelligence, medicine, pharmaceuticals, and patient-focused drug development.
This is why top pharma customers keep choosing us.

Validate commercial potential of disease maps

Determine the size and nature of commercial opportunities in new disease areas by measuring unmet needs and quality-of-life burdens in the largest focus group possible.

De-risk clinical trial execution

Predict appropriate endpoints and appropriate eligibility criteria to determine the suitability and success probability of clinical trial protocols prior to execution.


Tap into 50 million real-world patient experience data points to understand patients’ unmet needs, quality-of-life impacts, treatment experiences, wishes, needs, and uncertainties.

Long-term value development

Use AI and real-world data to build your own patient knowledge hub that learns over time, adds new data in real-time and enables your entire organisation to answer questions around patients’ experiences whenever you have to, how many times you need to.

Research acceleration

Our customers report an acceleration of 50% with large-scale evidence generation.

Turn real world data into real world evidence with Pharos, Semalytix‘s natural language processing platform

We provide pharmaceutical decision makers and other stakeholders in the health system with a full and accurate picture about patients needs on the basis of insight derived from an unprecedented data set comprised of the voices of 1,000,000,000 algorithmically verified patients.

HyperStream Graphic
Pharos Graphic
Sphinx AI Graphic

The largest real-time patient experience data stream on earth

Millions of real-time patient experiences across therapy areas at your fingertips

A world-class machine-reading artificial intelligence developed for and together with Pharma

You can count on us

AI-verified patient experience data points

Semalytix’s unparalleled data sources

Faster insight delivery, accelerating research timelines

Unique AI models to understand patients and physicians

Covered therapy areas

Oncology, Metabolism, Respiratory, Central nervous system, Immonology, Rare Diseases


Multi-lingual analysis

With somehow the haziness around defining AI and machine learning capabilities being in the growing curve of innovation, Semalytix comes to provide technology solutions, blended with consulting expertise to utilise the available vast amount of digital customer reactions, and turning them into multidimensional customers insights.

Wael R. Ayad
Sr. International Customer Insights Manager Oncology, Boehringer Ingelheim

I invested and joined the advisory board of Semalytix because I much enjoyed working with the Semalytix team and saw the huge potential of their solution. I was impressed by their world-leading approach in the field of semantic data analysis which is reflected in a compelling product and a number of outstanding customer references in the pharmaceutical industry. Ever since it has been impressive to see the company grow, advancing their product further, winning new customers and high profile investors. Two thumbs up for the whole Semalytix team!

Dr. Jan Brinckmann
Professor for Entrepreneurship and Strategy at ESADE

A great, fast-scaling team of world-leading Artificial Intelligence and Semantics experts working with blue-chip clients.”Exciting: Separating signal from noise”: Semalytix solves the oldest and biggest challenge facing information processing in the billion-dollar pharmaceutical market – and will hopefully do the same for other markets soon.

Dr. Ralf Struthoff
Owner/CEO of Dr. Struthoff GmbH

I am very happy to have the opportunity to join Semalytix as an investor, as I have not encountered a company for quite some time that provides such high customer value. Semalytix will improve the lives of many people, because the company provides answers to pharmaceutical questions related to the efficacy of drugs that, previously could only be answered- if at all – with considerable time and financial investment.

Oliver Flaskämper
Managing Director of Bitcoin Deutschland AG

Generally, I am very happy to support digital ventures, especially local projects such as the ones supported by the Founders Foundation or initiatives from the Pioneers Club. Semalytix is an exciting, regional and digital team with a truly innovative and highly sophisticated approach. The team researches and develops their own technologies based on artificial intelligence. I think that the personal knowledge transfer and the connection with the pharmaceutical industry are particularly well-suited.

Eduard R. Dörrenberg
Managing Director Dr. Kurt Wolff GmbH & Co. KG